Product news

Share this article:

Japanese pharmaceutical company Daiichi Sankyo said the FDA has approved Azor, a drug to treat high blood pressure. Azor will be co-marketed in the US with Forest Laboratories. The drug combines active ingredients in two existing drugs used to treat hypertension, Benicar, also co-marketed in the US by Daiichi Sankyo and Forest, and Pfizer's Norvasc. Azor is approved for use in patients with high blood pressure, or hypertension, who initially failed treatment on other medications.
Daiichi Sankyo is a unit of Japanese pharmaceutical company Daiichi Sankyo Co.

Amylin Pharmaceuticals announced that the FDA has approved the SymlinPen120 and the SymlinPen 60 pen-injector devices for administering Symlin (pramlintide acetate) injection. These new pre-filled pen-injector devices feature simple, fixed dosing to improve mealtime glucose control.
Adams Respiratory Therapeutics announced that the FDA approved its supplemental New Drug Application for a grape-flavored formulation of Delsym Extended-Release Suspension. The company will immediately commence distribution of grape Delsym product to its trade customers.

The FDA announced the approval of Novartis' Lamisil Oral Granules for the treatment of tinea capitis, a fungal infection of the scalp, in children ages 4 years and older.

UCB and Sanofi-Aventis announced that Xyzal, a new once-daily medication used to treat indoor and outdoor allergies, as well as chronic idiopathic urticaria, is now available by prescription in the U.S. Xyzal is an oral antihistamine that has been shown to provide powerful allergy symptom relief. Xyzal is approved for use in adults and children 6 years and older.

Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.